突变模式可识别对标准化疗反应良好的60岁及以上成人初发急性髓系白血病患者:Alliance研究分析
研究使用80个癌症和/或白血病相关基因的二代测序面板对423例60岁及以上初发急性髓系白血病患者进行分子分型,依据多变量模型及NPM1突变共存模式将患者分为完全缓解、无病生存和总生存的良好、中等和不良风险组,并显示所提标准可细化2017年欧洲白血病网分类。
要点
- 良好风险组完全缓解率81%,不良风险组32%,中等风险组50%。
- 良好风险组3年无病生存率和总生存率分别为46%和45%,不良遗传特征组仅2%和4%。
- 应用所提标准可细化2017年欧洲白血病网对接受化疗的老年患者的分类。
核心结论
- 应用所提标准可细化2017年欧洲白血病网对接受化疗的老年患者的分类。
研究设计与样本
- 使用80个癌症和/或白血病相关基因的二代测序面板对423例60岁及以上初发急性髓系白血病患者进行分子分型。
主要发现
- 良好风险组完全缓解率81%,不良风险组32%,中等风险组50%。
- 使用NPM1共存突变模式和SF1突变状态识别出3年无病生存率和总生存率分别为46%和45%的患者。
- 不良遗传特征组3年无病生存率和总生存率仅为2%和4%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thus far, only 5-15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens. We used a next-generation sequencing panel of 80 cancer- and/or leukemia-associated genes to profile molecularly 423 older patients with de novo AML. Using variables identified in multivariable models and co-occurring mutations in NPM1-mutated AML, we classified the patients into good-, intermediate-, and poor-risk groups for complete remission (CR) attainment, disease-free (DFS), and overall survival (OS). Whereas 81% of good-risk patients (comprising NPM1-mutated patients harboring mutations in chromatin remodeling, cohesin complex, methylation-related, spliceosome, and/or RAS pathway genes, FLT3-TKD, and/or patients without FLT3-ITD) achieved a CR, only 32% of poor-risk patients (with U2AF1, WT1 mutations and/or complex karyotype) did. Intermediate-risk patients had a 50% CR rate. Similarly, using NPM1 co-mutation patterns and SF1 mutation status, we identified patients with favorable DFS and OS 3-year rates of 46% and 45%, respectively. Patients with adverse genetic features had DFS and OS rates of only 2% and 4%. We show that application of our proposed criteria may refine the 2017 European LeukemiaNet classification for older patients treated with chemotherapy.
引用
- Eisfeld AK, Kohlschmidt J, Mrózek K, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018. PMID: 29563537. doi:10.1038/s41375-018-0068-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。